22 Jun 2011 07:00
Embargoed for release at 07.00 hours 22 June 2011
IPSO Ventures plc
("IPSO" or the "Company")
Shareholding in Biocroi Limited
IPSO Ventures plc (AIM: IPS) ("IPSO", the "Company"), the technology commercialisation business, is delighted to announce an addition to its investment portfolio.
In return for assisting with the creation of Biocroi Limited ("Biocroi"), a spin out from Trinity College Dublin, IPSO Management Limited, the Company's wholly owned subsidiary, has received a 10 per cent. shareholding in Biocroi.Biocroi was formed in 2011 and has developed a patented technology around multiwell plates. Multiwell plates or microtitre plates have become a standard tool in analytical research and clinical diagnostic testing. They are used extensively in the drug discovery/development process. This disruptive technology improves the quality and accuracy of results in the drug development process as well as offering the opportunity to miniaturise the multiwell plates.The other shareholders in Biocroi include Trinity College Dublin, the founders of Biocroi and certain other financial investors.
Further information, please contact:
IPSO Ventures plc Nick Rodgers, Chief Executive Officer
| Tel: 020 7921 2990 nick@ipsoventures.com www.ipsoventures.com
|
Allenby Capital Limited (Nominated adviser and broker) Nick Naylor Nick Athanas
| Tel: 020 3328 5656
|
Company description
IPSO Ventures plc is a business creator and active investor in new technologies, principally in the renewable energy and healthcare sector. Its experienced management team focuses on adding commercial value to enable young companies to move forward rapidly.